Skip Navigation

Nephrology Dialysis Transplantation 2007 22(Supplement 1):i1-i3; doi:10.1093/ndt/gfm087
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chapman, J. R.
Right arrow Articles by Campistol, J. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Chapman, J. R.
Right arrow Articles by Campistol, J. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Malignancy in renal transplantation: opportunities with proliferation signal inhibitors

Guest editors’ introduction

Jeremy R. Chapman1 and Josep M. Campistol2

1Director of Renal and Urology, Westmead Hospital, Westmead, NSW 2145, Australia and 2Director of the Nephrology and Urology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain

Correspondence and offprint requests to: J.R. Chapman, Centre for Transplant and Renal Research, Millennium Institute, University of Sydney, Westmead Hospital, Westmead, NSW 2145, Australia. Tel: +61 2 9845 6349; Fax: +61 2 9845 8300 Email: Jeremy_Chapman@wsahs.nsw.gov.au

Keywords: immunosuppression; malignancy; proliferation signal inhibitors/mTOR inhibitors; renal transplantation

The first 10% of the full text of this article appears below.

Patient survival after renal transplantation has improved considerably over the past 30 years [1]. Currently, patient survival rates of 95% at 1 year and ~90% at 5 years are realistic [2]; however, life expectancy remains far worse than in the general population [2].

Cardiovascular disease is the leading cause of death following renal transplantation in most countries, accounting for around 40–55% of all deaths [1], but post-transplant malignancies are becoming increasingly common and are fast becoming a major burden affecting long-term survival . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?